---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-000535"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:20:02.979350+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M

## Summary
- Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).
- GAAP net loss $10.7M ($0.26 loss/share); adjusted loss $0.04/share vs $0.08 loss prior year.
- Adjusted EBITDA $3.1M (vs $0.0M); FY25 guidance raised to $1-3M from loss of $2.5M-$0; adjusted loss per share guidance improved to $0.34-0.38.
- Received FDA 510(k) clearance for NanoKnife prostate tissue ablation and CPT Category I codes for IRE (effective Jan 2026).
- Cash $54.1M; operating cash flow $2.5M; $1.1M used on share repurchases in Q2.

## SEC filing metadata
- accession: 0001140361-25-000535
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036125000535/0001140361-25-000535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036125000535/ef20041243_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-000535
- JSON: https://secwatch.observer/filing/0001140361-25-000535.json
- Plain text: https://secwatch.observer/filing/0001140361-25-000535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.